Related Experiment Video
Updated: Aug 19, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Improving Reporter Gene Assay Methodology for Evaluating the Ability of Compounds to Restore P53 Activity
Xinle Han1,2, Jun Du3, Dandan Shi4
1Biomedical Research Institute, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, China.
Abstract:
Tumor suppressor protein P53 induces cycle arrest and apoptosis by mediating the transcriptional expression of its target genes. Mutations causing conformational abnormalities and post-translational modifications that promote degradation are the main reasons for the loss of P53 function in tumor cells. Reporter gene assays that can scientifically reflect the biological function can help discover the mechanism and therapeutic strategies that restore P53 function. In the reporter gene system of this work, tetracycline-inducible expression of wild-type P53 was used to provide a fully activated state as a 100% activity reference for the objective measurement of biological function. It was confirmed by RT-qPCR, cell viability assay, immunofluorescence, and Western blot analysis that the above-mentioned reporter gene system could correctly reflect the differences in biological activity between the wild-type and mutants. After that, the system was tentatively used for related mechanism research and compound activity evaluation. Through the tetracycline-induced co-expression of wild-type P53 and mutant P53 in exact proportion, it was observed that the response modes of typical transcriptional response elements (TREs) to dominant negative P53 mutation effect were not exactly the same. Compared to the relative multiple-to-solvent control, the activity percentage relative to the 100% activity reference of wild-type P53 can better reflect the actual influence of the so-called P53 mutant reactivator. Similarly, relative to the 100% activity reference, it can objectively reflect the biological effects caused by the inhibitor of P53 negative factors, such as MDM2. In conclusion, this study provides a 100% activity reference and a reliable calculation model for relevant basic research and drug development.
Insights
This study establishes a reporter gene system to quantify tumor suppressor P53 protein activity. This system provides a reliable reference for evaluating P53 function, aiding cancer research and drug development.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- Tumor suppressor protein P53 is crucial for cell cycle arrest and apoptosis.
- Loss of P53 function in cancer cells results from mutations and post-translational modifications.
- Reporter gene assays are valuable tools for studying P53 biological function and developing therapeutic strategies.
Purpose of the Study:
- To develop a reliable reporter gene system for objectively measuring P53 biological activity.
- To establish a 100% activity reference for wild-type P53.
- To validate the system's ability to differentiate between wild-type and mutant P53 activity and assess therapeutic interventions.
Main Methods:
- Utilized a tetracycline-inducible expression system for wild-type P53.
- Employed RT-qPCR, cell viability assays, immunofluorescence, and Western blot analysis for validation.
- Co-expressed wild-type and mutant P53 to study dominant-negative effects and evaluated P53 reactivators and MDM2 inhibitors.
Main Results:
- The reporter gene system accurately reflected biological activity differences between wild-type and mutant P53.
- Observed distinct response patterns of transcriptional response elements to dominant-negative P53 mutations.
- Demonstrated that activity percentage relative to the wild-type P53 reference objectively measures the impact of P53 reactivators and inhibitors.
Conclusions:
- The developed reporter gene system provides a 100% activity reference for wild-type P53.
- A reliable calculation model was established for assessing P53 function, mutant effects, and therapeutic interventions.
- This system supports basic research and drug development for restoring P53 function in cancer.

